Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CASP2 | P42575 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6087901 | 1.00 | CASP3 (0.49) | CASP3LMNACASP2CASP7CASP6 | |
| SCHEMBL6087977 | 0.89 | KDM4E (0.54) | CASP3LMNAMAPTKDM4EPKM | |
| SCHEMBL6087979 | 0.89 | KDM4E (0.54) | CASP3LMNAMAPTKDM4EPKM | |
| Cyclopropane SCHEMBL14715505 | 0.83 | KDR (0.40) | LMNAMAPTKDM4EKMT2AALDH1A1 | |
| SCHEMBL6105079 | 0.83 | ALDH1A1 (0.47) | LMNAMAPTKDM4EKMT2AALDH1A1 | |
| SCHEMBL6105082 | 0.83 | ALDH1A1 (0.47) | LMNAMAPTKDM4EKMT2AALDH1A1 | |
| SCHEMBL6103617 | 0.81 | ALDH1A1 (0.50) | CASP3LMNAMAPTKDM4EKMT2A | |
| SCHEMBL6088404 | 0.79 | ROCK2 (0.49) | LMNAMAPTKDM4EKMT2AALDH1A1 | |
| SCHEMBL6088413 | 0.79 | ROCK2 (0.49) | LMNAMAPTKDM4EKMT2AALDH1A1 | |
| SCHEMBL6087302 | 0.79 | MEN1 (0.44) | LMNAMAPTKDM4EKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490356-B1 | (3Z)-3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2013-02-27 | — | — | EP | claimed |
| US-20040019098-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2004-01-29 | — | — | US | claimed |
| US-6541504-B1 | Modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. | ALLERGAN SALES, LLC | 2003-04-01 | — | — | US | claimed |
| EP-1490356-B1 | (3Z)-3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| US-7060844-B2 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20060004084-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-01-05 | — | — | US | disclosed |
| US-20040019098-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2004-01-29 | — | — | US | disclosed |
| US-6541504-B1 | Modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. | ALLERGAN SALES, LLC | 2003-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004084-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | CDK2, ERBB2, MAP3K3 | CASP3 740/4885LMNA 3833/4885CASP2 1094/4885 |
| US-20040019098-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | CDK2, ERBB2, MAP3K3 | CASP3 783/4885LMNA 3822/4885CASP2 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.